Page 9 - Pharma Stocks

Zydus Life up 3% on mixed Q3, mcap tops Rs 1 trn; analysts split on outlook

Despite challenges from a lower-margin product mix, Zydus Life benefitted from forex gains and a favourable tax rate, which led to a PAT beat, analysts said

Ami Organics extends rally on strong Q3 results; stock zooms 30% in 4 days

The management believes, that on account of ramp-up of existing products, Fermion contract, and potential commercialisation of another CDMO contract in FY26E, Ami has strong revenue visibility.

Senores Pharmaceuticals races 17% on robust Q3; profit more than doubles

The rise in Senores Pharmaceuticals share came after the company's strong show in the December quarter (Q3FY25) results

Neuland Labs gets capex nod lift; stock up 5% even as broader indices sink

The company said it will spend Rs 254 crore for development and commercial production of Peptides for Generic Drug Substances (GDS) and Custom Manufacturing Solutions (CMS) business.

Indoco Remedies drops 4% on weak Q3 performance; revenue falls 11% YoY

Indoco Remedies share dropped after the company reported a weak set of numbers in the December quarter of financial year 2025 (Q3FY25)

Venus Remedies share price surges 12% on renewal of EU GMP certification

The rise in Venus Remedies share price came after the company announced the renewal of its European GMP certification by Infarmed, the National Authority of Medicines and Health Products in Portugal

Glenmark Pharma share rises 2% as unit launches blood clotting drug

The uptick in Glenmark Pharmaceuticals share price came after the company announced the launch of Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules

Zydus Life up 2% on USFDA nod for Phase II(b) clinical trial for Usnoflast

Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS

AstraZeneca Pharma share price rises 3% on CDSCO nod for Eculizumab

AstraZeneca share rose after it that the company has secured permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from CDSCO

Biocon extends rally, up 6% in 2 days on HSBC, Motilal Oswal 'Buy' upgrade

Notably, Biocon share price has surged about 6 per cent in the last two sessions

Dr. Reddy's pops 4% after Nuvama upgrades to 'Buy'; arm sells US mfg unit

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy' from 'Reduce'

Nifty outlook indecisive, says Vinay Rajani; picks 2 stocks to buy today

Stocks to Buy Today: Narayana Hrudalaya and Pfizer shares have been rising with heavy volumes

Laurus Labs hits 2-yr high on hopes of healthy earnings; up 44% in 3 months

The board of directors of Laurus are scheduled to meet on January 24 to announce the financial results of the company for the quarter ended December 31, 2024.

Aarti Pharma share price down 5% from day high on order to shut Vapi plant

Aarti Pharma share price: The Gujarat Pollution Control Board has ordered Aarti Pharma to deposit a bank guarantee of Rs 2,50,000

Supriya Lifescience share price soars 7% in weak market today; here's why

Supriya Lifescience Chairman and Whole-Time Director Satish Wagh said he was confident of achieving 22 per cent year-on-year revenue growth in the current financial year (FY25)

Akums Drugs signs agreement with leading Euro Co; share price gains 5%

Akums share price: Akums group will manufacture and supply multiple SKUs of Oral Liquid Formulation to be marketed in multiple European countries by the global Company

Aster DM hits 8-month high, up 30% in 2 months on healthy growth outlook

Given its impressive revenue CAGR of 22 per cent through FY19-24 with improving profitability, analysts at Elara Capital expects strong growth to continue, though at moderated levels.

Here's why Aurobindo Pharma gained 2% in trade on December 23; details here

Aurobindo Pharma share rose after it announced that CuraTeQ Biologics s.r.o., a step-down subsidiary of company, has obtained marketing authorisation from UK's MHRA for Bevqolva

Market outlook 2025: IT, chemicals, banks among top sectors to invest

Experts suggest investors should expect moderate returns as the market adjusts to global macroeconomic challenges

Here's why Alembic Pharma was buzzing in trade on December 20, details here

Alembic Pharma share rose after the company announced that it has received final approval from the USFDA for its ANDA Divalproex Sodium Delayed-Release Capsules USP, 125 mg